Howbrook David N, van der Valk Anne M, O'Shaughnessy Meg C, Sarker Dipak K, Baker Simon C, Lloyd Andrew W
School of Pharmacy and Biomolecular Sciences, University of Brighton, Moulsecoomb, Brighton BN2 4GJ, UK.
Drug Discov Today. 2003 Jul 15;8(14):642-51. doi: 10.1016/s1359-6446(03)02773-9.
The focus of high-throughput drug discovery has progressed through the genome and the transcriptome and is now moving towards more difficult problems in assessing the proteome, glycome and metabolome. Microarrays are currently the major tool in the assessment of gene expression via cDNA or RNA analysis; however, they are also used to screen libraries of proteins and small molecules. Microarrays have helped to extract more information from smaller sample volumes and enabled the incorporation of low-cost high-throughput assays in the drug discovery process. The technology continues to develop and is being rapidly transferred into more challenging areas, with the potential to further aid and enhance the drug discovery process through the development of, for example, proteomic, glycomic and tissue arrays.
高通量药物研发的重点已从基因组和转录组发展而来，目前正朝着评估蛋白质组、糖组和代谢组等更具挑战性的问题迈进。微阵列目前是通过cDNA或RNA分析评估基因表达的主要工具；然而，它们也被用于筛选蛋白质和小分子文库。微阵列有助于从更小的样本量中提取更多信息，并使低成本高通量检测能够纳入药物研发过程。该技术不断发展，并正在迅速应用于更具挑战性的领域，有潜力通过例如蛋白质组学、糖组学和组织阵列的开发，进一步辅助和加强药物研发过程。
